Proactiveinvestors recommends
Additional Information
Market: NYSE
Sector: Pharmaceuticals
EPIC: EBS
Latest Price: 18.27  (4.04% Ascending)
52-week High: 24.98
52-week Low: 15.02
Market Cap: 654.99M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Emergent BioSolutions
www.emergentbiosolutions.com

Emergent BioSolutions is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease.

Full Emergent BioSolutions profile here
Pdf

Emergent BioSolutions Begins Phase I Trial for Inhalational Anthrax Treatment Drug

8th Sep 2010, 5:34 pm
Emergent BioSolutions Begins Phase I Trial for Inhalational Anthrax Treatment Drug

Biopharmaceutical company Emergent BioSolutions (NYSE:EBS) has said that the Phase I clinical trial for its anthrax monoclonal antibody drug, designed to treat symptoms of inhalational anthrax disease, has begun.

The Phase I clinical trial, involving 50 healthy volunteers, is a randomized, double-blind, placebo-controlled, dose escalation study designed to evaluate the safety and pharmacokinetics of the monoclonal antibody candidate, said the company.

"This milestone reaffirms Emergent's commitment to leading the development of medical countermeasures that address inhalational anthrax as a biological threat," senior vice president of product development at Emergent, Stephen Lockhart.

Emergent received clearance from the U.S. FDA to proceed with the Phase I clinical trial in May of this year.

The study is being funded by the Biomedical Advance Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID), as well as the National Institutes of Health (NIH) and Department of Health and Human Services (HHS).

Emergent is focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body's immune system to prevent or treat disease.

Its marketed product, BioThrax, is the only vaccine approved by the U.S. FDA for the prevention of anthrax infection.

The company's product pipeline targets infectious diseases and includes programs focused on anthrax, tuberculosis, typhoid, flu and chlamydia.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.